|
12 Nov 2013 |
Isis Pharmaceuticals Earns $1.5M from the Advancement of the Phase 2 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
|
|
12 Nov 2013 |
Promethera Biosciences successfully enrols twenty patients in its multicentric phase I/II trial
|
|
11 Nov 2013 |
Alnylam Reports Positive Phase II Data for Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR), and Initiates Phase III Trial
|
|
08 Nov 2013 |
Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
|
|
06 Nov 2013 |
Cellular Biomedicine Group Receives Approval for Phase IIb Clinical Trial of ReJoin™ for Treatment of Knee Osteoarthritis (KOA)
|
|
04 Nov 2013 |
Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution and Reduction in the HIV DNA Reservoir In Subjects with Long-Term Infection
|
|
04 Nov 2013 |
Arrowhead Presents Data Suggesting ARC-520 Induces Therapeutic Flare in Chronic Hepatitis B
|
|
04 Nov 2013 |
Positive Preclinical Profile of RG-101, a GalNAc-conjugated anti-miR Targeting microRNA-122, Supports Clinical Development for the Treatment of HCV
|
|
04 Nov 2013 |
Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
|
